TY - JOUR
T1 - Live two-way video versus face-to-face treatment for depression, anxiety, and obsessive-compulsive disorder
T2 - A 24-week randomized controlled trial
AU - Kishimoto, Taishiro
AU - Kinoshita, Shotaro
AU - Kitazawa, Momoko
AU - Hishimoto, Akitoyo
AU - Asami, Takeshi
AU - Suda, Akira
AU - Bun, Shogyoku
AU - Kikuchi, Toshiaki
AU - Sado, Mitsuhiro
AU - Takamiya, Akihiro
AU - Mimura, Masaru
AU - Sato, Yasunori
AU - Takemura, Ryo
AU - Nagashima, Kengo
AU - Nakamae, Takashi
AU - Abe, Yoshinari
AU - Kanazawa, Tetsufumi
AU - Kawabata, Yasuo
AU - Tomita, Hiroaki
AU - Abe, Koichi
AU - Hongo, Seiji
AU - Kimura, Hiroshi
AU - Sato, Aiko
AU - Kida, Hisashi
AU - Sakuma, Kei
AU - Funayama, Michitaka
AU - Sugiyama, Naoya
AU - Hino, Kousuke
AU - Amagai, Toru
AU - Takamiya, Maki
AU - Kodama, Hideyuki
AU - Goto, Kenichi
AU - Fujiwara, Shuichiro
AU - Kaiya, Hisanobu
AU - Nagao, Kiichiro
N1 - Publisher Copyright:
© 2023 The Authors. Psychiatry and Clinical Neurosciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Psychiatry and Neurology.
PY - 2024/4
Y1 - 2024/4
N2 - Aim: Live two-way video, easily accessible from home via smartphones and other devices, is becoming a new way of providing psychiatric treatment. However, lack of evidence for real-world clinical setting effectiveness hampers its approval by medical insurance in some countries. Here, we conducted the first large-scale pragmatic, randomized controlled trial to determine the effectiveness of long-term treatment for multiple psychiatric disorders via two-way video using smartphones and other devices, which are currently the primary means of telecommunication. Methods: This randomized controlled trial compared two-way video versus face-to-face treatment for depressive disorder, anxiety disorder, and obsessive-compulsive disorder in the subacute/maintenance phase during a 24-week period. Adult patients with the above-mentioned disorders were allocated to either a two-way video group (≥50% video sessions) or a face-to-face group (100% in-person sessions) and received standard treatment covered by public medical insurance. The primary outcome was the 36-Item Short-Form Health Survey Mental Component Summary (SF-36 MCS) score. Secondary outcomes included all-cause discontinuation, working alliance, adverse events, and the severity rating scales for each disorder. Results: A total of 199 patients participated in this study. After 24 weeks of treatment, two-way video treatment was found to be noninferior to face-to-face treatment regarding SF-36 MCS score (48.50 vs 46.68, respectively; p < 0.001). There were no significant differences between the groups regarding most secondary end points, including all-cause discontinuation, treatment efficacy, and satisfaction. Conclusion: Two-way video treatment using smartphones and other devices, was noninferior to face-to-face treatment in real-world clinical settings. Modern telemedicine, easily accessible from home, can be used as a form of health care.
AB - Aim: Live two-way video, easily accessible from home via smartphones and other devices, is becoming a new way of providing psychiatric treatment. However, lack of evidence for real-world clinical setting effectiveness hampers its approval by medical insurance in some countries. Here, we conducted the first large-scale pragmatic, randomized controlled trial to determine the effectiveness of long-term treatment for multiple psychiatric disorders via two-way video using smartphones and other devices, which are currently the primary means of telecommunication. Methods: This randomized controlled trial compared two-way video versus face-to-face treatment for depressive disorder, anxiety disorder, and obsessive-compulsive disorder in the subacute/maintenance phase during a 24-week period. Adult patients with the above-mentioned disorders were allocated to either a two-way video group (≥50% video sessions) or a face-to-face group (100% in-person sessions) and received standard treatment covered by public medical insurance. The primary outcome was the 36-Item Short-Form Health Survey Mental Component Summary (SF-36 MCS) score. Secondary outcomes included all-cause discontinuation, working alliance, adverse events, and the severity rating scales for each disorder. Results: A total of 199 patients participated in this study. After 24 weeks of treatment, two-way video treatment was found to be noninferior to face-to-face treatment regarding SF-36 MCS score (48.50 vs 46.68, respectively; p < 0.001). There were no significant differences between the groups regarding most secondary end points, including all-cause discontinuation, treatment efficacy, and satisfaction. Conclusion: Two-way video treatment using smartphones and other devices, was noninferior to face-to-face treatment in real-world clinical settings. Modern telemedicine, easily accessible from home, can be used as a form of health care.
KW - anxiety disorder
KW - depression
KW - long-term treatment
KW - obsessive-compulsive disorder
KW - two-way video
UR - https://www.scopus.com/pages/publications/85180166349
UR - https://www.scopus.com/pages/publications/85180166349#tab=citedBy
U2 - 10.1111/pcn.13618
DO - 10.1111/pcn.13618
M3 - Article
C2 - 38102849
AN - SCOPUS:85180166349
SN - 1323-1316
VL - 78
SP - 220
EP - 228
JO - Psychiatry and Clinical Neurosciences
JF - Psychiatry and Clinical Neurosciences
IS - 4
ER -
SDG 3 すべての人に健康と福祉を